Page 3 - Cellmid Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically significant 7,000 level now coming back into view. Over the week as a whole , the FTSE 100 added ar...

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically significant 7,000 level now coming back into view. Over the week as a whole , the FTSE 100 added ar...

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically significant 7,000 level now coming back into view. Over the week as a whole , the FTSE 100 added ar...

Cellmid on track for profitability in FY2022 with planned revenue growth in ecommerce and new product launches The company has made progress in its new product development program with a hair loss supplement formulation completed and manufacturing and ecommerce set to launch during the first half of 2022. Cellmid is well-funded to implement its growth strategy after completing a $4.5 million capital raise in March, taking cash reserves to around $8.3 million after costs. Cellmid Ltd (ASX:CDY) is on track for profitability in the 2022 financial year with planned revenue growth in ...

Cellmid rights issue raises $3.81 million with strong support and plans follow-on placement for additional $700,000 Its lead manager and underwriter received bids from institutional and professional investors in excess of the available shortfall. Together with the follow-on placement, the company will raise a total of $4,516,369 before costs Cellmid Ltd’s (ASX:CDY) renounceable rights issue has raised $3,816,369, with strong support from existing shareholders and new institutional and professional investors.  Lead manager and underwriter Mahe Capital Pty Ltd received bids from...